VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2015 | An overview of daratumumab monotherapy for heavily treated multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, summarises the potential of the anti-CD38 monoclonal antibody, daratumumab, as a novel, well-tolerated, single-agent therapy for patients with heavily treated multiple myeloma.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter